• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白质组中的化学变构现象。

Chemoisosterism in the proteome.

机构信息

Chemogenomics Laboratory, Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and University Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Catalonia, Spain.

出版信息

J Chem Inf Model. 2013 Feb 25;53(2):279-92. doi: 10.1021/ci3002974. Epub 2013 Jan 24.

DOI:10.1021/ci3002974
PMID:23312010
Abstract

The concept of chemoisosterism of protein environments is introduced as the complementary property to bioisosterism of chemical fragments. In the same way that two chemical fragments are considered bioisosteric if they can bind to the same protein environment, two protein environments will be considered chemoisosteric if they can interact with the same chemical fragment. The basis for the identification of chemoisosteric relationships among protein environments was the increasing amount of crystal structures available currently for protein-ligand complexes. It is shown that one can recover the right location and orientation of chemical fragments constituting the native ligand in a nuclear receptor structure by using only chemoisosteric environments present in enzyme structures. Examples of the potential applicability of chemoisosterism in fragment-based drug discovery are provided.

摘要

引入蛋白质环境的化学等价性概念,作为化学片段生物等价性的补充性质。如果两个化学片段可以结合到相同的蛋白质环境中,则认为它们具有生物等价性;同样地,如果两个蛋白质环境可以与相同的化学片段相互作用,则认为它们具有化学等价性。目前,用于蛋白质-配体复合物的晶体结构越来越多,这为鉴定蛋白质环境之间的化学等价性关系提供了依据。结果表明,仅使用酶结构中存在的化学等价性环境,就可以恢复核受体结构中原配体中化学片段的正确位置和取向。提供了化学等价性在基于片段的药物发现中的潜在应用实例。

相似文献

1
Chemoisosterism in the proteome.蛋白质组中的化学变构现象。
J Chem Inf Model. 2013 Feb 25;53(2):279-92. doi: 10.1021/ci3002974. Epub 2013 Jan 24.
2
Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.天然产物质谱:一种支持基于结构和基于片段的药物发现的“ESI”方法。
Future Med Chem. 2010 Jan;2(1):35-50. doi: 10.4155/fmc.09.141.
3
X-ray crystallography in drug discovery.药物研发中的X射线晶体学
Methods Mol Biol. 2009;572:31-56. doi: 10.1007/978-1-60761-244-5_3.
4
Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank.类药性密度:一种基于蛋白质数据库中大量口袋和类药性配体来量化蛋白质靶标“可结合性”的方法。
J Chem Inf Model. 2010 Nov 22;50(11):2029-40. doi: 10.1021/ci100312t. Epub 2010 Oct 26.
5
LigPlot+: multiple ligand-protein interaction diagrams for drug discovery.LigPlot+:用于药物发现的多种配体-蛋白质相互作用图。
J Chem Inf Model. 2011 Oct 24;51(10):2778-86. doi: 10.1021/ci200227u. Epub 2011 Oct 5.
6
PDB-Ligand: a ligand database based on PDB for the automated and customized classification of ligand-binding structures.PDB-配体:一个基于蛋白质数据银行(PDB)的配体数据库,用于配体结合结构的自动和定制分类。
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D238-41. doi: 10.1093/nar/gki059.
7
sc-PDB-Frag: a database of protein-ligand interaction patterns for Bioisosteric replacements.sc-PDB-Frag:用于生物电子等排体替代的蛋白质-配体相互作用模式数据库。
J Chem Inf Model. 2014 Jul 28;54(7):1908-18. doi: 10.1021/ci500282c. Epub 2014 Jul 17.
8
Off-target networks derived from ligand set similarity.源自配体集相似性的脱靶网络。
Methods Mol Biol. 2009;575:195-205. doi: 10.1007/978-1-60761-274-2_8.
9
SHOP: a method for structure-based fragment and scaffold hopping.SHOP:一种基于结构的片段和骨架跳跃方法。
ChemMedChem. 2009 Mar;4(3):427-39. doi: 10.1002/cmdc.200800355.
10
Structure-based drug discovery and protein targets in the CNS.基于结构的药物发现和中枢神经系统的蛋白质靶标。
Neuropharmacology. 2011 Jan;60(1):7-23. doi: 10.1016/j.neuropharm.2010.07.016. Epub 2010 Jul 29.

引用本文的文献

1
Chemoinformatics and artificial intelligence colloquium: progress and challenges in developing bioactive compounds.化学信息学与人工智能研讨会:生物活性化合物开发的进展与挑战
J Cheminform. 2022 Dec 2;14(1):82. doi: 10.1186/s13321-022-00661-0.
2
Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.基于片段的虚拟筛选鉴定出亨廷顿病的首个临床前候选药物。
Sci Rep. 2022 Nov 16;12(1):19642. doi: 10.1038/s41598-022-21900-2.
3
Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.
以神经退行性疾病为重点的治疗性药物重新定位:威胁与问题
Front Pharmacol. 2022 Oct 3;13:1007315. doi: 10.3389/fphar.2022.1007315. eCollection 2022.
4
CAVIAR: a method for automatic cavity detection, description and decomposition into subcavities.CAVIAR:一种自动检测、描述和分解腔隙的方法。
J Comput Aided Mol Des. 2021 Jun;35(6):737-750. doi: 10.1007/s10822-021-00390-w. Epub 2021 May 29.
5
Insights into Computational Drug Repurposing for Neurodegenerative Disease.计算药物重用到神经退行性疾病的研究进展。
Trends Pharmacol Sci. 2019 Aug;40(8):565-576. doi: 10.1016/j.tips.2019.06.003. Epub 2019 Jul 17.
6
In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery.基于片段的/基于结构的药物发现的新工具:计算片段映射方法。
J Comput Aided Mol Des. 2018 Nov;32(11):1229-1245. doi: 10.1007/s10822-018-0160-8. Epub 2018 Sep 8.
7
On the Integration of Drug Design Methods for Drug Repurposing.论用于药物再利用的药物设计方法的整合
Front Pharmacol. 2017 May 23;8:298. doi: 10.3389/fphar.2017.00298. eCollection 2017.
8
Polypharmacology in Precision Oncology: Current Applications and Future Prospects.精准肿瘤学中的多靶点药物治疗:当前应用与未来前景
Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828.